CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 82 enrolled
Drug / intervention
Clofarabine +3 moredrug
Likely dose
Melphalan 140 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00943592
NCT00943592Phase 2Completed
CompareCT.gov

Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

University of Chicago·interventional·Posted Jul 22, 2009·Updated Feb 27, 2014

In Brief

A Phase 2 clinical trial evaluating Clofarabine, Melphalan, and 2 other interventions for Advanced Hematologic Malignancies and 2 related conditions. Completed, enrolled 82 participants across 1 site.

Detailed Summary

This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Hematologic Malignancies, Leukemia, Preleukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2009
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2011
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 16.9 years ago

Interventions

Clofarabinedrug

Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).

Melphalandrug

Doses ranging from 100 to 140 mg/m2

Campathdrug

20mg/d x5

Stem Cell Transplantprocedure

Infusion of donor, bone marrow and auto.